Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

AVEO, Astellas Say Tivozanib Superior To Sorafenib In Advanced RCC - Quick Facts

RELATED NEWS
Trade AVEO now with 

AVEO Pharmaceuticals, Inc. (AVEO: Quote) and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Tuesday said that tivozanib Phase 3 clinical trial demonstrated superiority over sorafenib in the primary endpoint of progression-free survival in patients with advanced renal cell carcinoma.

TIVO-1, a global, randomized Phase 3 clinical trial evaluated the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma. TIVO-1 is the first registration study in first-line renal cell carcinoma that is comparing an investigational agent against an approved VEGF therapy.

The companies noted that tivozanib demonstrated a well-tolerated safety profile consistent with the Phase 2 experience; the most commonly reported side effect was hypertension, a well established on-target and manageable effect of VEGFR inhibitors

Based on these data, AVEO and Astellas currently plan to submit for marketing approval of tivozanib in the US and Europe in 2012.

Click here to receive FREE breaking news email alerts for AVEO Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Toyota Motor Corp. (TM, TYT.L) Thursday announced 1.1 percent decline in worldwide production for October, as there was a sharp decline in production of passenger cars in Japan. Production outside Japan improved 2.3 percent. In a separate announcement, the Japanese automaker said it will recall more... Computer and printer maker Hewlett-Packard Co. said Tuesday after the markets closed that its fourth quarter profit fell 6% from last year, as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. This organic and natural products company has experienced strong compounded annual growth over the last four fiscal years with its net sales growing 25% and adjusted income from continuing operations over 30%.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.